Crispr Therapeutics, a biopharmaceutical company, has raised According to a release, the company on
The funding and the team's collective expertise will allow CRISPR Therapeutics to translate its technology into important new gene medicines that have the potential to cure serious genetic diseases at the molecular level.
Cas9 is an enzyme that can be easily programmed with RNA to cut DNA at targeted sites within the genome,1-2 enabling the deletion, insertion or correction of target genes with surgical precision. It allows scientists and clinicians to mutate genes of interest and to correct specific target genes, to tackle both recessive and dominant genetic diseases. CRISPR-Cas9 genome editing offers significant advantages over traditional gene therapy approaches, which to date have only been useful in correcting some recessive genetic disorders.
"The efficiency and ease of use of CRISPR-Cas9 have led to the scientific community rapidly adopting the technology on an unprecedented scale," said Dr
Crispr Therapeutics' scientific founders are:
Crispr Therapeutics has secured rights to the foundational intellectual property covering the use of CRISPR-Cas9 genome editing in human therapeutics. The company in-licensed the technology from Dr Charpentier, who co-invented the Crispr-Cas9 technology.1-2
"Crispr-Cas9 has truly democratized genome editing, with many areas of research being transformed due to the technology's ease of use and broad applicability," said Dr Charpentier. "The collective efforts of the broader academic research community are in turn driving tremendous progress in the field."
((Comments on this story may be sent to firstname.lastname@example.org))
Crispr Therapeutics, a biopharmaceutical company, has raised
According to a release, the company on